Neurogene has been on a huge run in 2024. That came to a halt after the company released trial results. But, the results may be better than the market thinks.
Investors in Acadia Pharmaceuticals Inc. ACAD need to pay close attention to the stock based on moves in the options market lately. That is because the Jan. 17, 2025 $3.00 Call had some of the highest...
Axsome Therapeutics’ AXSM Auvelity (AXS-05) was launched in the United States in 2022 for the treatment of major depressive disorder (MDD), making it the first approved drug in the company’s portfolio.Auvelity...
Investors in Acadia Pharmaceuticals Inc. ACAD need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 20, 2024 $29 Call had some of the highest implied...
March S&P 500 E-Mini futures (ESH24) are trending up +0.30% this morning as market participants awaited the all-important U.S. consumer inflation report that could shed light on the Federal Reserve’s...